title: Membrane binding sites and non-genomic effects of estrogen in cultured human pre-osteoclastic cells.
abstract: Besides functional estrogen receptors, the presence of signalling cell surface binding sites for 17beta-estradiol (17betaE2) has been reported in osteoblast- and osteoclast-like cells, suggesting that 17betaE2 may influence bone remodelling by a dual mechanism of action: to affect gene expression mediated by the nuclear activity of the steroid-receptor complex, and to initiate rapid responses triggered by a signal-generating receptor on the cell surface. Recently, we demonstrated that the human pre-osteoclastic cell line FLG 29.1 bears functional estrogen receptors. In this study we examined FLG 29.1 cells for the presence of cell surface binding sites for 17betaE2, and whether 17betaE2 could elicit cell signalling. Using a cell-impermeant and fluorescent estrogen conjugate, 17beta-estradiol-6-carboxymethyloxime-bovine serum albumin-fluorescein isothiocyanate, we demonstrated the presence of specific plasma membrane binding sites for 17betaE2. Stimulation of FLG 29.1 cells with low (1 nM) and high (1 microM) doses of 17betaE2 induced a prompt and significant (P < 0.05) increase of cellular pH, as measured in single cells using an image analysis system. In addition, both cAMP and cGMP were significantly increased by 17betaE2 with a dose-dependent response. Finally, a rapid increase of intracellular calcium ion concentration [Ca2+] was also induced by 1 nM 17betaE2, as measured in single cells using an image analysis system. Our findings strongly suggest a non-genomic action of 17betaE2 on osteoclast precursors.
authors.affiliation: Department of Clinical Physiopathology, University of Florence, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fiorelli
authors.forename: F
authors.initials: F
authors.lastname: Gori
authors.forename: U
authors.initials: U
authors.lastname: Frediani
authors.forename: F
authors.initials: F
authors.lastname: Franceschelli
authors.forename: A
authors.initials: A
authors.lastname: Tanini
authors.forename: C
authors.initials: C
authors.lastname: Tosti-Guerra
authors.forename: S
authors.initials: S
authors.lastname: Benvenuti
authors.forename: L
authors.initials: L
authors.lastname: Gennari
authors.forename: L
authors.initials: L
authors.lastname: Becherini
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
mesh_terms: D002118:Calcium / Q000378:metabolism*; D002454:Cell Differentiation; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D004958:Estradiol / Q000378:metabolism / Q000494:pharmacology*; D000091344:Filaggrin Proteins; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D007948:Leukemia, Monocytic, Acute; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011959:Receptors, Estradiol / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D011959:Receptors, Estradiol; D004958:Estradiol; D000242:Cyclic AMP; D006152:Cyclic GMP; D002118:Calcium